DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ovarian hyperstimulation syndrome — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian hyperstimulation syndrome maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian hyperstimulation syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
progesterone receptor (PGR) — PGR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 14beta,17alphadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1SQN · 1.451 Å · ligand (14beta,17alpha)-17-ethynyl-17-hydroxyestr-4-en-3-one (NDR). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Human Reproduction · 1999 · 13 citations
Ovarian hyperstimulation syndrome
AbstractDear Sir, The opinion expressed by Grudzinskas and Egbase (1998) on the prevention of ovarian hyperstimulation syndrome (OHSS) contains some interesting ideas. OHSS is a major cause of morbidity and mortality after ovulation stimulation strategies for assisted conception. However, I feel that the current vogue to perform ovarian diathermy/laser vaporization is an unhealthy one. The mechanism of action of ovarian diathermy is still unclear but it appears that surgery to the polycystic ovary sensitizes the ovary to endogenous follicle stimulating hormone (FSH), so that the previously anovulatory ovary either spontaneously ovulates or becomes more sensitive to exogenous stimulation (e.g. clomiphene citrate), whereas previously it had been unresponsive. Furthermore, only minimal damage is required to achieve ovulation as we showed when bilateral ovarian activity followed unilateral ovarian diathermy (Balen and Jacobs, 1994). In order to be able to reduce the chance of the ovary over responding to exogenous gonadotrophins, as demonstrated by Rimington et al. (1997), a considerable amount of ovarian destruction is required (M.R.Rimington, personal communication). This can only be at the expense of destroying healthy ovarian tissue and reducing the oocyte store—an area of ongoing research in our laboratories. We would, therefore, urge caution before proceeding to ovarian destruction prior to stimulation and would suggest instead that reducing the dose of gonadotrophins used is an inherently better way to proceed. In the future, the in-vitro maturation of oocytes from unstimulated, or mildly stimulated ovaries may well be a promising alternative.
The pathophysiology and treatment of ovarian hyperstimulation syndrome
AbstractThe ovarian hyperstimulation syndrome (OHSS) remains one of the enigmas of reproductive medicine. We all fear its development in our patients and we all have “pet” policies for its prevention and treatment. Despite this, its incidence has not changed significantly in the last 20 years with the severe form still occurring in 0.3–5.0% of cycles. Its pathogenesis clearly has a physiological basis but it would appear to be compounded by the body's homeostatic response to the changes produced by the syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
